Placebo + ACI-7104.056 at Dose A + ACI-7104.056 at Dose B (optional) + ACI-7104.056 at Dose C (optional)

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Parkinson Disease 6, Early-Onset

Trial Timeline

Jul 24, 2023 → Jan 1, 2028

NCT ID

NCT06015841

About Placebo + ACI-7104.056 at Dose A + ACI-7104.056 at Dose B (optional) + ACI-7104.056 at Dose C (optional)

Placebo + ACI-7104.056 at Dose A + ACI-7104.056 at Dose B (optional) + ACI-7104.056 at Dose C (optional) is a phase 2 stage product being developed by AC Immune for Parkinson Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06015841. Target conditions include Parkinson Disease, Parkinson Disease 6, Early-Onset.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Lemborexant + placeboEisaiApproved

✅Safinamide MesilateEisaiApproved

✅Istradefylline PillKyowa KirinApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06015841	Phase 2	Active	Jul 24, 2023	Jan 1, 2028	Parkinson Disease

Competing Products

20 competing products in Parkinson Disease

See all competitors

Product	Company	Stage	Hype Score
exidavnemab + Placebo Comparator	BioArctic AB	Phase 2	36
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
LY4006896 + Placebo	Eli Lilly	Phase 1	36
ATH-1017 + Placebo	LeonaBio	Phase 2	17
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Approved	43
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
Equfina 50 mg	Eisai	Pre-clinical	26
Equfina	Eisai	Pre-clinical	26
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
Safinamide Mesilate	Eisai	Approved	43
E2007 + E2007 + E2007	Eisai	Phase 2	35